Abstract
Two cases show osimertinib/sotorasib combination could be effective in KRAS G12C-driven osimertinib resistance.
MeSH terms
-
Humans
-
Mutation
-
Proto-Oncogene Proteins p21(ras)* / genetics
Substances
-
osimertinib
-
sotorasib
-
Proto-Oncogene Proteins p21(ras)
-
KRAS protein, human